Oncology nursing community Oncology Nurses Can Have a Global Impact—in Bhutan and Beyond August 24, 2017
Topic Biotherapy ASCO Annual Meeting Study Assesses Response to Pembrolizumab Based on Biomarkers in Patients With Soft Tissue or Bone Sarcomas The multicenter, phase II SAR028 clinical trial was the first to study pembrolizumab monotherapy in patients with soft tissue sarcoma or bone sarcoma to assess the clinical efficacy signals in multiple histologies. The researchers presented extended follow-up data at the ASCO Annual Meeting. June 02, 2017 Clinical practice What Is Chemotherapy Competence Versus Chemotherapy Certification? The ONS clinical inbox frequently receives questions about whether nurses need to be “chemotherapy certified” to give specific chemotherapy and/or biotherapy agents. January 28, 2017 Biotherapy Biosimilar Treatments Have Practice Implications As biosimilars continue to gain popularity in cancer care, healthcare workers should be prepared to see them in their practice. Here’s what you need to know about this newer drug product. April 05, 2016 Trending Topics Treatments Safety Research Standards ONS Congress Clinical practice U.S. Food and Drug Administration (FDA) Immunotherapy Cancer research Oncology nursing community View All Topics
ASCO Annual Meeting Study Assesses Response to Pembrolizumab Based on Biomarkers in Patients With Soft Tissue or Bone Sarcomas The multicenter, phase II SAR028 clinical trial was the first to study pembrolizumab monotherapy in patients with soft tissue sarcoma or bone sarcoma to assess the clinical efficacy signals in multiple histologies. The researchers presented extended follow-up data at the ASCO Annual Meeting. June 02, 2017
Clinical practice What Is Chemotherapy Competence Versus Chemotherapy Certification? The ONS clinical inbox frequently receives questions about whether nurses need to be “chemotherapy certified” to give specific chemotherapy and/or biotherapy agents. January 28, 2017
Biotherapy Biosimilar Treatments Have Practice Implications As biosimilars continue to gain popularity in cancer care, healthcare workers should be prepared to see them in their practice. Here’s what you need to know about this newer drug product. April 05, 2016
